A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427)
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms KEYNOTE-427
- Sponsors Merck Sharp & Dohme
- 17 Oct 2016 Planned End Date changed from 1 Apr 2020 to 1 May 2020.
- 17 Oct 2016 Planned primary completion date changed from 1 Apr 2020 to 1 May 2020.
- 17 Oct 2016 Status changed from not yet recruiting to recruiting.